Methamphetamine Use Disorder
3
Pipeline Programs
2
Companies
4
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Angeles TherapeuticsCA - Los Angeles
3 programs2
1
naltrexone plus bupropionPhase 1/21 trial
MirtazapinePhase 11 trial
Pomaglumetad methionilPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
Angeles Therapeuticsnaltrexone plus bupropion
Angeles TherapeuticsMirtazapine
Angeles TherapeuticsPomaglumetad methionil
Colorado TherapeuticsSham TMS
Clinical Trials (4)
Total enrollment: 103 patients across 4 trials
Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder
Start: Nov 2013Est. completion: Feb 201549 patients
Phase 1/2Completed
Mirtazapine and Methamphetamine Drug-drug Interaction Study
Start: May 2021Est. completion: May 202415 patients
Phase 1Completed
Study of Pomaglumetad and Methamphetamine
Start: Aug 2017Est. completion: Jul 202019 patients
Phase 1Terminated
Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder
Start: Sep 2024Est. completion: May 202820 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 103 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.